Who is sponsoring NCT01433029?

NCT01433029 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT01433029?

Interventions in NCT01433029: Surgical Video Assessments, Video Recording of CAB.

What condition does NCT01433029 study?

NCT01433029 studies Other Surgical Procedures.

Is NCT01433029 still recruiting?

NCT01433029 is currently completed. Last updated 30 January 2017.

Last reviewed 2017-01-30 · How we verify

NCT01433029

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Objective Assessment of Technical Skills in Cardiothoracic Surgery

Completed Last updated 30 January 2017

What this trial tests

trial testing Surgical Video Assessments in Other Surgical Procedures in 8 participants. Completed in 22 January 2017.

Timeline

1 September 2011

Primary endpoint
22 January 2017

22 January 2017

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Status	Completed
Study type	OBSERVATIONAL
Enrollment	8
Start date	1 September 2011
Primary completion	22 January 2017
Estimated completion	22 January 2017
Sites	6 locations across United States

Drugs / interventions tested

Surgical Video Assessments
Video Recording of CAB

Conditions studied

Other Surgical Procedures — all drugs for Other Surgical Procedures →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

21 and older, any sex, with Other Surgical Procedures. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this research study is to develop a method of rating videos of CAB procedures that will produce a reliable assessment of a cardiothoracic surgical trainee's technical proficiency. In addition, researchers also want to learn if using a video manual to train raters can help improve rater reliability.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01433029 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 30 January 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01433029.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing